In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Rise of Regional Dealmaking

Executive Summary

Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.

Related Content

Co-Promotes: A Marketplace Reality, But Do They Make Sense?
NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
Specialty Pharma: Tapping Japan
Auctions: Getting the Best Value for Your Asset
Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
Merck's Deal Focus
Bayer Wins Specialty CV Deal
Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts